Ayla Eser1, Ilknur Inegol Gumus2, Husamettin Erdamar3, Ikbal Kaygusuz2, Melahat Yildirim4, Betul Usluogullari5, Muzeyyen Duran Erdolu6, Serap Aynur Simavli7, Ramazan Yigitoglu3, Nilgun Ozturk Turhan8. 1. Department of Obstetrics and Gynecology, Turgut Ozal University Medical School, Ankara, Turkey. Electronic address: aylaacar76@yahoo.com.tr. 2. Department of Obstetrics and Gynecology, Turgut Ozal University Medical School, Ankara, Turkey. 3. Department of Biochemistry, Turgut Ozal University Medical School, Ankara, Turkey. 4. Department of Obstetrics and Gynecology, Ataturk Education and Research Hospital, Ankara, Turkey. 5. Department of Obstetrics and Gynecology, Cengiz Gokcek Hospital, Gaziantep, Turkey. 6. Department of Obstetrics and Gynecology, Sevket Yilmaz Education and Research Hospital, Bursa, Turkey. 7. Department of Obstetrics and Gynecology, Pamukkale University Medical School, Denizli, Turkey. 8. Department of Obstetrics and Gynecology, Sitki Kocman University Medical School, Mugla, Turkey.
Abstract
OBJECTIVE: The aim of this study was to investigate factors associated with thrombosis that may contribute to recurrent pregnancy loss (habitual abortion), specifically differences in serum levels of platelet-activating factor and thrombin-activatable fibrinolysis inhibitor (carboxypeptidase B2) between women with a history of recurrent miscarriage and those with no recurrent miscarriage history. MATERIALS AND METHODS: A case-controlled, prospective study design was adopted to compare women with a history of two or more first-trimester miscarriages (n = 42) with those with no history of recurrent miscarriage (n = 36). Participants were recruited from the Department of Obstetrics and Gynecology of Turgut Ozal University Hospital. Platelet-activating factor and thrombin-activatable fibrinolysis inhibitor levels in serum samples were measured by an enzyme-linked immunosorbent assay. RESULTS: Platelet-activating factor levels were significantly (p = 0.018) higher in the recurrent miscarriage group. There was no difference in levels of thrombin-activatable fibrinolysis inhibitor expression between the groups. CONCLUSION: Platelet-activating factor is significantly higher in serum of patients with a history of recurrent miscarriage than in those without such a history, with potential implications for placental function and fetal growth, which could be relevant to miscarriage recurrence. Larger studies are indicated to further examine these findings.
OBJECTIVE: The aim of this study was to investigate factors associated with thrombosis that may contribute to recurrent pregnancy loss (habitual abortion), specifically differences in serum levels of platelet-activating factor and thrombin-activatable fibrinolysis inhibitor (carboxypeptidase B2) between women with a history of recurrent miscarriage and those with no recurrent miscarriage history. MATERIALS AND METHODS: A case-controlled, prospective study design was adopted to compare women with a history of two or more first-trimester miscarriages (n = 42) with those with no history of recurrent miscarriage (n = 36). Participants were recruited from the Department of Obstetrics and Gynecology of Turgut Ozal University Hospital. Platelet-activating factor and thrombin-activatable fibrinolysis inhibitor levels in serum samples were measured by an enzyme-linked immunosorbent assay. RESULTS: Platelet-activating factor levels were significantly (p = 0.018) higher in the recurrent miscarriage group. There was no difference in levels of thrombin-activatable fibrinolysis inhibitor expression between the groups. CONCLUSION: Platelet-activating factor is significantly higher in serum of patients with a history of recurrent miscarriage than in those without such a history, with potential implications for placental function and fetal growth, which could be relevant to miscarriage recurrence. Larger studies are indicated to further examine these findings.